We investigated the comparative effects of the RAAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) on the DPP-4-associated mesenchymal activation in diabetic kidney and its implication in renal fibrosis. Here, ACE is linked to renal fibrosis.